{
    "root": "5bec0e35-b44e-4712-a29d-021160b52810",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FAMOTIDINE",
    "value": "20250509",
    "ingredients": [
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ],
    "indications": {
        "text": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : \u2022active duodenal ulcer ( du ) . \u2022active gastric ulcer ( gu ) . \u2022symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . \u2022erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : \u2022treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . \u2022reduction risk duodenal ulcer recurrence .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "zollinger-ellison syndrome (DOID:0050782)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050782"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "zollinger-ellison syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_913"
            }
        ]
    },
    "contraindications": {
        "text": "indication recommended ( 2.1 ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastric ulcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; 40 mg twice daily adults pathological hypersecretory conditions 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du recurrence 20 mg daily \u2022 full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( 2.1 , 2.2 ) ( 2.3 ) : \u2022 take daily bedtime twice daily morning bedtime without food .",
        "doid_entities": [
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "famotidine tablets supplied , round , white off-white film-coated tablets , debossed \u201c v \u201d one side \u201c 16 \u201d side . bottles 14 ndc 68788-8518-4 bottles 30 ndc 68788-8518-3 bottles 60 ndc 68788-8518-6 bottles 90 ndc 68788-8518-9 storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15-30\u00b0c ( 59-86\u00b0f ) ( usp controlled room temperature ) . dispense usp tight , light-resistant container .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:\n                  \n                     \n                        \u2022active duodenal ulcer (DU).\n                     \n                        \u2022active gastric ulcer (GU).\n                     \n                        \u2022symptomatic nonerosive gastroesophageal reflux disease (GERD).\n                     \n                        \u2022erosive esophagitis due to GERD, diagnosed by biopsy.\n                  \n                  Famotidine tablets are indicated in adults for the:\n                  \n                     \n                        \u2022treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).\n                     \n                        \u2022reduction of the risk of duodenal ulcer recurrence.",
    "contraindications_original": "Indication Recommended Dosage ( 2.1 ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily \u2022 See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1, 2.2 ) Administration ( 2.3 ): \u2022 Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions_original": "Famotidine tablets are supplied as, round, white to off-white Film-coated tablets, debossed with \u201cV\u201d on one side and \u201c16\u201d on the other side.\n                  \n                     \n                        \u00a0Bottles of 14\tNDC 68788-8518-4\n                     \n                        \u00a0Bottles of 30\tNDC 68788-8518-3\n                     \n                        \u00a0Bottles of 60\tNDC 68788-8518-6\n                     \n                        \u00a0Bottles of 90\tNDC 68788-8518-9\n                  \n                  Storage\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F) (See USP Controlled Room Temperature).\u00a0Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists.",
    "drug": [
        {
            "name": "FAMOTIDINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        }
    ]
}